

INVENTOR SEARCH

=> fil capl
 FILE 'CAPLUS' ENTERED AT 14:33:03 ON 01 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
 FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> => d que nos l41
L3      39 SEA FILE=REGISTRY ABB=ON (116046-53-8/BI OR 128095-14-7/BI OR
1583-88-6/BI OR 1655-07-8/BI OR 21615-34-9/BI OR 22396-14-1/BI
OR 404-70-6/BI OR 51756-10-6/BI OR 52721-69-4/BI OR 5538-51-2/BI
I OR 607-97-6/BI OR 609-14-3/BI OR 611-10-9/BI OR 64-04-0/BI
OR 780771-35-9/BI OR 780771-36-0/BI OR 780771-37-1/BI OR
780771-38-2/BI OR 780771-39-3/BI OR 780771-40-6/BI OR 780771-41
-7/BI OR 780771-42-8/BI OR 780771-43-9/BI OR 780771-44-0/BI OR
780771-45-1/BI OR 780771-46-2/BI OR 780771-47-3/BI OR 780771-48
-4/BI OR 780771-49-5/BI OR 780771-50-8/BI OR 780771-51-9/BI OR
780771-52-0/BI OR 780771-54-2/BI OR 780771-55-3/BI OR 780771-56
-4/BI OR 780771-57-5/BI OR 780771-58-6/BI OR 85796-29-8/BI OR
916335-88-1/BI)
L38      1 SEA FILE=CAPLUS ABB=ON US2006-551920/AP
L40      12524 SEA FILE=CAPLUS ABB=ON L3
L41      1 SEA FILE=CAPLUS ABB=ON L40 AND L38
```

=> fil casre; d que nos l29
 FILE 'CASREACT' ENTERED AT 14:34:13 ON 01 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 26 Jan 2008 VOL 148 ISS 5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*   CASREACT now has more than 13.8 million reactions
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1      STR
L2      448706 SEA FILE=REGISTRY SSS FUL L1
L4      46492 SEA FILE=REGISTRY ABB=ON L2 AND CASREACT/LC
L5      10919 SEA FILE=CASREACT ABB=ON L4
L8      STR
L11     1257 SEA FILE=CASREACT SUB=L5 SSS FUL L8 ( 11881 REACTIONS)
L21 (   29)SEA FILE=CASREACT ABB=ON SHCHERBAKOVA I?/AU
L22 (   0)SEA FILE=CASREACT ABB=ON BALANDRIA M?/AU
L23 (  108)SEA FILE=CASREACT ABB=ON HUANG G?/AU
L24 (   5)SEA FILE=CASREACT ABB=ON GEOFFROY O?/AU
L25 (  117)SEA FILE=CASREACT ABB=ON FOX J?/AU
L26 (   51)SEA FILE=CASREACT ABB=ON NAIR S?/AU
L27 (   7)SEA FILE=CASREACT ABB=ON BALANDRIN M?/AU
L28     4 SEA FILE=CASREACT ABB=ON (L21 AND (L22 OR L23 OR L24 OR L25
      OR L26 OR L27)) OR (L23 AND (L24 OR L25 OR L26 OR L27)) OR
      (L24 AND (L25 OR L26 OR L27)) OR (L25 AND (L26 OR L27)) OR
      (L26 AND L27)
L29     4 SEA FILE=CASREACT ABB=ON L28 OR (L28 AND L11)
```

=> dup rem l41,l29

FILE 'CAPLUS' ENTERED AT 14:34:22 ON 01 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 14:34:22 ON 01 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
 PROCESSING COMPLETED FOR L41
 PROCESSING COMPLETED FOR L29
 L42 4 DUP REM L41 L29 (1 DUPLICATE REMOVED)
 ANSWER '1' FROM FILE CAPLUS
 ANSWERS '2-4' FROM FILE CASREACT

=> d ibib abs hitstr 1; d iall 2-4

L42 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STN DUPLICATE 1
 ACCESSION NUMBER: 2004:902339 CAPLUS Full-text
 DOCUMENT NUMBER: 141:379934
 TITLE: Preparation of 2,3,5,6-tetrasubstituted
 3H-pyrimidin-4-ones via cyclization of carboxamides.
 INVENTOR(S): Shcherbakova, Irina; Balandrin, Manuel; Huang,
 Guangfei; Geoffroy, Otto; Fox, John; Nair, Satheesh K.
 PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 33 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092121	A2	20041028	WO 2004-US10639	20040407
WO 2004092121	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1613606 A2 20060111 EP 2004-749815 20040407 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR JP 2006522160 T 20060928 JP 2006-509759 20040407 US 2007161792 A1 20070712 US 2006-551920 20061120 <-- PRIORITY APPLN. INFO.: US 2003-460859P P 20030407 US 2003-479323P P 20030618 WO 2004-US10639 W 20040407				

OTHER SOURCE(S): CASREACT 141:379934; MARPAT 141:379934

AB The title process is claimed. Thus, 3-(2-(2-acetoxybenzoylamino)-2-methylbut-2-enoic acid phenethylamide (preparation given) was refluxed overnight with KOH in EtOH/H₂O to give 37% 2-(2-hydroxyphenyl)-5,6-dimethyl-3-phenethyl-3H-pyrimidin-4-one.


IT 780771-35-9P 780771-40-6P 780771-41-7P
 780771-42-8P 780771-43-9P 780771-44-0P
 780771-45-1P 780771-46-2P 780771-47-3P
 780771-48-4P 780771-51-9P 780771-52-0P
 780771-54-2P 780771-55-3P 780771-56-4P
 780771-57-5P 780771-58-6P 916335-88-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of tetrasubstituted pyrimidinones via cyclization of carboxamides)


RN 780771-35-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5,6-dimethyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-40-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-41-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-42-8 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-43-9 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-44-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-45-1 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-46-2 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-47-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-propyl- (CA INDEX NAME)




RN 780771-48-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-51-9 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-methoxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-52-0 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-54-2 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 780771-56-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-57-5 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 780771-58-6 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3-[2-(3-fluorophenyl)ethyl]-3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 916335-88-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)-5-(trifluoromethyl)- (CA INDEX NAME)



IT 64-04-0, Phenethylamine 404-70-6, 3-Fluorophenethylamine

607-97-6, Ethyl 2-ethyl-3-oxobutyrate 609-14-3, Ethyl

2-methyl-3-oxobutyrate 611-10-9, Ethyl 2-

oxocyclopentanecarboxylate 1583-88-6, 4-Fluorophenethylamine

1655-07-8, Ethyl 2-oxocyclohexanecarboxylate 5538-51-2

21615-34-9 22396-14-1 51756-10-6


52721-63-4, 2-Fluorophenethylamine 116046-53-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tetrasubstituted pyrimidinones via cyclization of carboxamides)


RN 64-04-0 CAPLUS

CN Benzeneethanamine (CA INDEX NAME)



RN 404-70-6 CAPLUS

CN Benzeneethanamine, 3-fluoro- (CA INDEX NAME)




RN 607-97-6 CAPLUS

CN Butanoic acid, 2-ethyl-3-oxo-, ethyl ester (CA INDEX NAME)



RN 609-14-3 CAPLUS

CN Butanoic acid, 2-methyl-3-oxo-, ethyl ester (CA INDEX NAME)




RN 611-10-9 CAPLUS

CN Cyclopentanecarboxylic acid, 2-oxo-, ethyl ester (CA INDEX NAME)



RN 1583-88-6 CAPLUS

CN Benzeneethanamine, 4-fluoro- (CA INDEX NAME)



RN 1655-07-8 CAPLUS

CN Cyclohexanecarboxylic acid, 2-oxo-, ethyl ester (CA INDEX NAME)



RN 5538-51-2 CAPLUS


CN Benzoyl chloride, 2-(acetyloxy)- (CA INDEX NAME)




RN 21615-34-9 CAPLUS
 CN Benzoyl chloride, 2-methoxy- (CA INDEX NAME)




RN 22396-14-1 CAPLUS
 CN Cyclopropaneacetic acid, α -acetyl-, ethyl ester (CA INDEX NAME)




RN 51756-10-6 CAPLUS
 CN Butanoic acid, 2-acetyl-3-methyl-, methyl ester (CA INDEX NAME)




RN 52721-69-4 CAPLUS
 CN Benzeneethanamine, 2-fluoro- (CA INDEX NAME)




RN 116046-53-8 CAPLUS
 CN Butanoic acid, 3-oxo-2-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




IT 85796-29-8P 128095-14-7F 780771-36-0P
 780771-37-1P 780771-38-2P 780771-39-3P
 780771-49-5P, 3-Amino-2-isopropylbut-3-enoic acid methyl ester
 780771-50-8P, 2-Isopropyl-3-(2-methoxybenzoylamino)but-3-enoic
 acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tetrasubstituted pyrimidinones via cyclization of
 carboxamides)
 RN 85796-29-8 CAPLUS
 CN 1,3-Dioxolane-2-acetic acid, α ,2-dimethyl- (CA INDEX NAME)




RN 128095-14-7 CAPLUS
 CN 1,3-Dioxolane-2-acetic acid, α ,2-dimethyl-, methyl ester (CA INDEX
 NAME)



RN 780771-36-0 CAPLUS
 CN 1,3-Dioxolane-2-acetamide, α ,2-dimethyl-N-(2-phenylethyl)- (CA
 INDEX NAME)




RN 780771-37-1 CAPLUS
 CN Butanamide, 2-methyl-3-oxo-N-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-38-2 CAPLUS

CN 2-Butenamide, 3-amino-2-methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-39-3 CAPLUS

CN Benamide, 2-(acetyloxy)-N-[1,2-dimethyl-3-oxo-3-[(2-phenylethyl)amino]-1-propenyl]- (9CI) (CA INDEX NAME)




RN 780771-49-5 CAPLUS

CN 3-Butenoic acid, 3-amino-2-(1-methylethyl)-, methyl ester (CA INDEX NAME)



RN 780771-50-8 CAPLUS

CN 3-Butenoic acid, 3-[(2-methoxybenzoyl)amino]-2-(1-methylethyl)-, methyl ester (CA INDEX NAME)



L42 ANSWER 2 OF 4 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 143:59927 CASREACT [Full-text](#)

TITLE: Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones

AUTHOR(S): Shcherbakova, Irina; Huang, Guangfei
; Geoffroy, Otto J.; Nair, Satheesh

K.; Swierczek, Krzysztof; Balandrin, Manuel
 F.; Fox, John; Heaton, William L.;
 Conklin, Rebecca L.

CORPORATE SOURCE: Drug Discovery, NPS Pharmaceuticals, Inc., Salt Lake
 City, UT, 84108, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005),
 15(10), 2537-2540

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 28-16 (Heterocyclic Compounds (More Than One Hetero
 Atom))

Section cross-reference(s): 1

GRAPHIC IMAGE:



I

ABSTRACT:

Design, synthesis, structure-activity relationship studies and calcium receptor antagonist (calcilytic) properties of 3H-pyrimidin-4-ones, e.g., I, are described. The pyrimidinones were synthesized by multistep procedures.

SUPPL. TERM: keto ester amidine heterocyclization; pyrimidinone prepn
 calcilytic

INDEX TERM: Amines, reactions

ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (aralkyl; preparation, calcilytic activity, and
 structure-activity relationship of substituted
 pyrimidinones starting from hydroxybenzonitrile or
 β -keto esters and phenylethylamines using multistep
 procedures)

INDEX TERM: Receptors

ROLE: BSU (Biological study, unclassified); BIOL (Biological
 study)

(calcium; preparation, calcilytic activity, and
 structure-activity relationship of substituted
 pyrimidinones starting from hydroxybenzonitrile or
 β -keto esters and phenylethylamines using multistep
 procedures)

INDEX TERM: Carboxylic acids, reactions

ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (oxo, esters; preparation, calcilytic activity, and
 structure-activity relationship of substituted
 pyrimidinones starting from hydroxybenzonitrile or
 β -keto esters and phenylethylamines using multistep
 procedures)

INDEX TERM: Heterocyclization

(preparation, calcilytic activity, and structure-activity
 relationship of substituted pyrimidinones starting from

hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)

INDEX TERM: Structure-activity relationship (receptor-binding, CaR; preparation, calcilytic activity, and structure-activity relationship of substituted pyrimidinones starting from hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)

INDEX TERM: 780771-32-6P 780771-33-7P 780771-34-8P 780771-35-9P
780771-41-7P 780771-43-9P 780771-44-0P 780771-47-3P
780771-48-4P 780771-53-1P 780771-54-2P 780771-55-3P
780771-56-4P 780771-57-5P 780771-58-6P
ROLE: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, calcilytic activity, and structure-activity relationship of substituted pyrimidinones starting from hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)

INDEX TERM: 64-04-0, 2-Phenylethylamine 105-45-3, Methyl acetoacetate 344-00-3 404-70-6, 2-(3-Fluorophenyl)ethylamine 607-97-6 609-14-3 611-10-9 611-20-1, 2-Hydroxybenzonitrile 1522-46-9 1540-28-9 1655-07-8 5538-51-2, 2-Acetoxybenzoyl chloride 22396-14-1 52721-69-4, 2-(2-Fluorophenyl)ethylamine
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(preparation, calcilytic activity, and structure-activity relationship of substituted pyrimidinones starting from hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)

INDEX TERM: 4746-93-4P 7646-61-9P 13747-72-3P 23153-73-3P
26384-76-9P 27773-09-7P 27773-10-0P 38853-85-9P
85796-29-8P 90647-54-4P 130625-27-3P 610754-95-5P
751428-10-1P 780771-36-0P 780771-37-1P 780771-38-2P
780771-39-3P 854132-93-7P 854132-94-8P 854132-95-9P
854132-96-0P 854132-97-1P 854132-98-2P 854132-99-3P
854133-00-9P 854133-01-0P 854133-02-1P 854133-03-2P
854133-04-3P 854133-05-4P 854133-06-5P 854133-07-6P
854133-08-7P 854133-09-8P 854133-10-1P 854133-11-2P
854133-12-3P 854133-13-4P 854133-14-5P 854133-15-6P
854133-16-7P 854133-17-8P 854133-18-9P 854133-19-0P
854133-20-3P 854133-21-4P 854133-22-5P 854133-23-6P
854133-24-7P 854133-25-8P 854133-26-9P 854133-27-0P
854133-28-1P 854133-29-2P 854133-30-5P 854133-31-6P
854133-32-7P 854133-33-8P 854133-34-9P 854133-35-0P
854133-36-1P 854133-37-2P 854133-38-3P 854133-39-4P
854133-40-7P 854133-41-8P 854133-42-9P 854133-43-0P
854133-44-1P 854133-45-2P 854133-46-3P 854133-47-4P
854133-48-5P 854133-49-6P 854133-50-9P 854133-51-0P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, calcilytic activity, and structure-activity relationship of substituted pyrimidinones starting from hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Altmann, E; WO 2004/056365 A2 CAPLUS
(2) Balmforth, A; Br J Pharmacol 1994, V112, P277 MEDLINE

- (3) Beerli, R; WO 02/102782 A2 CAPLUS
- (4) Beerli, R; 2002 CAPLUS
- (5) Eerdekens, M; Schizophrenia Res 2004, V70, P91
- (6) Fox, J; Bone 1997, V21, P163 CAPLUS
- (7) Fox, J; Curr Opin Pharmacol 2002, V2, P338 CAPLUS
- (8) Gowen, M; J Clin Invest 2000, V105, P1595 CAPLUS
- (9) Jeong, J; Org Lett 2004, V6, P1013 CAPLUS
- (10) Jezewski, A; J Heterocycl Chem 2001, V38, P645 CAPLUS
- (11) Kessler, A; ChemBioChem 2004, V5, P1131 CAPLUS
- (12) Madhavan, G; Bioorg Med Chem Lett 2002, V12, P2671
- (13) Nemeth, E; J Mol Endocrinol 2002, V29, P15 CAPLUS
- (14) Nemeth, E; J Pharmacol Exp Ther 2001, V299, P323 CAPLUS
- (15) Petrel, C; J Biol Chem 2004, V278, P18990
- (16) Pinner, A; Chem Ber 1889, V22, P1612
- (17) Salimbeni, A; J Med Chem 1995, V38, P4806 CAPLUS
- (18) Shcherbakova, I; WO 2004/031755 A2 CAPLUS
- (19) Shcherbakova, I; WO 2004/092120 A2 CAPLUS
- (20) Shcherbakova, I; WO 2004/092121 A2 CAPLUS
- (21) Shcherbakova, I; 2004 CAPLUS
- (22) Shcherbakova, I; 2004 CAPLUS
- (23) Shcherbakova, I; 2004 CAPLUS
- (24) Shcherbakova, I; Bioorg Med Chem Lett 2005, V15, P1557 CAPLUS
- (25) Shcherbakova, I; Drugs Future 2004, V29(Suppl A), P331
- (26) Sitte, A; Chem Ber 1969, V102, P615 CAPLUS
- (27) Takahashi, T; J Chem Soc, Perkin Trans 1 1988, P2653 CAPLUS
- (28) Tice, C; Tetrahedron 2001, V57, P2689 CAPLUS
- (29) Yang, W; WO 2004/106296 A2 CAPLUS
- (30) Yang, W; Bioorg Med Chem Lett 2005, V15, P1225 CAPLUS

=> d ibib abs ind 3-4

L42 ANSWER 3 OF 4 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 142:348143 CASREACT Full-text
 TITLE: 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis
 AUTHOR(S): Shcherbakova, Irina; Baiandrin, Manuel F.; Fox, John; Ghatak, Anjan; Heaton, William L.; Conklin, Rebecca L.
 CORPORATE SOURCE: Drug Discovery, NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(6), 1557-1560
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Structure-activity relationship studies, focused on identification of the active pharmacophore fragments in a single high-throughput screening calcilytic hit, resulted in the discovery of potent calcium receptor antagonists, substituted 3H-quinazolin-4-ones.
 CC 1-3 (Pharmacology)
 ST Section cross-reference(s): 28
 IT quinazolinone deriv prepn structure osteoporosis
 IT Bone resorption inhibitors
 IT Osteoporosis
 IT Structure-activity relationship
 IT (3H-quinazolin-4-ones preparation and structure-related potential for

osteoporosis treatment)

IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (calcium; 3H-quinazolin-4-ones preparation and structure-related potential
 for osteoporosis treatment)

IT 7440-70-2, Calcium, biological studies 9002-64-6, Parathyroid hormone
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

IT 691378-86-6P 849233-11-0P 849233-12-1P
 RL: BYP (Byproduct); PREP (Preparation)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

IT 312277-73-9P 450378-70-8P 489416-64-0P 691378-17-3P 691378-21-9P
 691378-24-2P 691378-25-3P 691378-26-4P 691378-28-6P 691378-34-4P
 691378-45-7P 691378-46-8P 691378-47-9P 691378-49-1P 691378-50-4P
 691378-53-7P 691378-54-8P 691378-65-1P 691378-94-6P 849233-10-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

IT 328540-74-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

IT 64-04-0, Benzeneethanamine 89-77-0 98-88-4, Benzoyl chloride
 100-07-2 118-92-3 393-52-2 404-70-6 434-76-4 446-08-2 446-32-2
 635-21-2 825-22-9 1711-05-3 1711-07-5 2941-78-8 4389-45-1
 4389-50-8 5538-51-2 13078-79-0 16446-73-4 21615-34-9 27914-73-4
 37785-02-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

IT 1022-46-4P 18595-84-1P 18600-55-0P 35673-24-6P 60681-96-1P
 117979-60-9P 213340-78-4P 298682-51-6P 306750-40-3P 311775-86-7P
 331973-01-4P 691379-08-5P 691379-09-6P 691379-10-9P 691379-11-0P
 691379-12-1P 691379-13-2P 691379-21-2P 691379-22-3P 861891-42-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (3H-quinazolin-4-ones preparation and structure-related potential for
 osteoporosis treatment)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 4 OF 4 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 141:366249 CASREACT Full-text

TITLE: Preparation of pyrimidinone compounds as calcilytics

INVENTOR(S): Shcherbakova, Irina V.; Balandrin,
 Manuel F.; Huang, Guangfei;
 Geoeffroy, Otto; Fox, John; Marquis,
 Robert; Yamashita, Dennis Shinji; Luengo, Juan; Wang,
 Wenyong

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA; Glaxosmithkline

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092120	A2	20041028	WO 2004-US10638	20040407
WO 2004092120	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230903	A1	20041028	AU 2004-230903	20040407
CA 2521129	A1	20041028	CA 2004-2521129	20040407
EP 1615897	A2	20060118	EP 2004-749814	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1835928	A	20060920	CN 2004-80009255	20040407
JP 2006522159	T	20060928	JP 2006-509758	20040407
MX 2005PA10683	A	20060801	MX 2005-PA10683	20051004
US 2007197555	A1	20070823	US 2006-552363	20061120
PRIORITY APPLN. INFO.:			US 2003-460859P	20030407
			US 2003-479323P	20030618
			WO 2004-US10638	20040407

OTHER SOURCE(S): MARPAT 141:366249
GI



- AB Title compds. I [R1-2 = H, halo, CN, CF3, etc.; R3 = aryl; R4 = H, alkyl, etc.] are prepared For instance, 2-(2-Hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one is prepared from o-hydroxybenzonitrile, acetyl chloride and Me acetoacetate. Compds. of the invention have IC50 values < 30 μ M in a calcium receptor inhibition assay. I are useful for the treatment of abnormal bone or mineral homeostasis.
- IC ICM C07D
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
- ST pyrimidinone calcilytic calcium receptor antagonist prepn
- IT Bone, disease
(Paget's; preparation of pyrimidinone compds. as calcilytics)
- IT Homeostasis
(bone or mineral disorders; preparation of pyrimidinone compds. as calcilytics)
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (calcium; preparation of pyrimidinone compds. as calcilytics)
- IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of pyrimidinone compds. as calcilytics)
- IT Antirheumatic agents
Human
Osteoarthritis
Osteoporosis
Periodontium, disease
Rheumatoid arthritis
Wound healing
(preparation of pyrimidinone compds. as calcilytics)
- IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia; preparation of pyrimidinone compds. as calcilytics)
- IT 9002-64-6, Parathyroid hormone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrimidinone compds. as calcilytics)
- IT 780771-43-9P, 5-Ethyl-2-(2-hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one 780771-51-9P, 3-[2-(3-Fluorophenyl)ethyl]-5-isopropyl-2-(2-methoxyphenyl)-6-methyl-3H-pyrimidin-4-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidinone compds. as calcilytics)
- IT 780771-32-6P, 2-(2-Hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one 780771-33-7P, 3-[2-(2-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-34-8P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-35-9P, 2-(2-Hydroxyphenyl)-5,6-dimethyl-3-phenethyl-3H-pyrimidin-4-one 780771-40-6P, 3-[2-(2-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-41-7P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-42-8P, 3-[2-(4-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-44-0P, 5-Ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-45-1P 780771-46-2P, 5-Ethyl-3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-47-3P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-propyl-3H-pyrimidin-4-one 780771-48-4P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-isopropyl-6-methyl-3H-pyrimidin-4-one 780771-52-0P, 3-[2-(2-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-isopropyl-6-methyl-3H-pyrimidin-4-one 780771-53-1P, 2-(2-Hydroxyphenyl)-5-methyl-3-phenethyl-6-trifluoromethyl-3H-pyrimidin-4-one 780771-54-2P, 2-(2-Hydroxyphenyl)-3-phenethyl-5,6,7,8-tetrahydro-3H-quinazolin-4-one 780771-55-3P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one 780771-56-4P, 5-Cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-57-5P, 2-(2-Hydroxyphenyl)-3-phenethyl-5,6,7-tetrahydrocyclopenta[1,2-d]pyrimidin-4-one 780771-58-6P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-3,5,6,7-tetrahydrocyclopenta[1,2-d]pyrimidin-4-one 780771-59-7P, 5-Ethyl-2-(2-methoxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one 780771-60-0P, 2-(5-Chloro-2-hydroxyphenyl)-3-yl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-62-2P, 5-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-64-4P, 5-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-65-5P, 5-Ethyl-2-(2-fluoro-6-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-67-7P, 2-(5-Chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-68-8P,

2-(5-Bromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-69-9P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-3-isopropylphenyl)-6-methyl-3H-pyrimidin-4-one 780771-71-3P, 2-(3,5-Dibromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-72-4P, 5-Ethyl-2-(3-chloro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-74-6P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-3-methylphenyl)-6-methyl-3H-pyrimidin-4-one 780771-75-7P, 2-(4-Chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-76-8P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-4-methoxyphenyl)-6-methyl-3H-pyrimidin-4-one
 RL: PACO (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

- (preparation of pyrimidinone compds. as calcilytics)
- IT 64-04-0, Phenethylamine 75-36-5, Acetyl chloride 100-58-3, Phenylmagnesium bromide 105-45-3, Methyl acetoacetate 404-70-6, 2-(3-Fluorophenyl)ethylamine 607-97-6, 2-Ethyl-3-oxobutanoic acid ethyl ester 609-14-3, 2-Methyl-3-oxobutyric acid ethyl ester 611-10-9, 2-Oxocyclopentanecarboxylic acid ethyl ester 611-20-1, o-Hydroxybenzoxonitrile 1522-46-9, 2-Isopropyl-3-oxobutanoic acid ethyl ester 1540-28-9, 2-Propyl-3-oxobutanoic acid ethyl ester 1583-88-6, 4-Fluorophenethylamine 1655-07-8, 2-Oxocyclohexanecarboxylic acid ethyl ester 5485-91-6, Acetic acid 4-bromo-2-chlorocarbonylphenyl ester 5538-51-2, Acetic acid 2-chlorocarbonylphenyl ester 5538-52-3, Acetic acid 2-chlorocarbonyl-4-fluorophenyl ester 5538-53-4, Acetic acid 4-chloro-2-chlorocarbonylphenyl ester 17094-21-2, 2-Methyl-3-oxobutanoic acid methyl ester 19202-27-8, Acetic acid 2-chlorocarbonylmethoxyphenyl ester 21615-34-9 22396-14-1, 2-Cyclopropyl-3-oxobutanoic acid ethyl ester 26384-76-9 27893-05-6, Acetic acid 2-chlorocarbonyl-6-methylphenyl ester 52721-69-4, 2-(2-Fluorophenyl)ethylamine 54223-78-8 54551-50-7, Acetic acid 5-chloro-2-chlorocarbonylphenyl ester 116046-53-8, 2-Trifluoromethyl-3-oxobutanoic acid ethyl ester 780771-61-1, 2-Acetoxy-5-chloronicotinoyl chloride 780771-63-3, Acetic acid 2-chlorocarbonyl-6-fluorophenyl ester 780771-66-6, Acetic acid 2-chlorocarbonyl-3-fluorophenyl ester 780771-70-2, Acetic acid 2-chlorocarbonyl-6-isopropylphenyl ester 780771-73-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
- (preparation of pyrimidinone compds. as calcilytics)
- IT 27773-09-7P, 2-(2-Methyl-[1,3]dioxolan-2-yl)propionic acid ethyl ester 61636-46-2P 85796-29-8P, 2-(2-Methyl-[1,3]dioxolan-2-yl)propionic acid 780771-36-0P, 2-(2-Methyl-[1,3]dioxolan-2-yl)-N-phenethylpropanamide 780771-37-1P, 2-Methyl-3-oxo-N-phenethylbutyramide 780771-38-2P, 3-Amino-2-methylbut-2-enoic acid phenethylamide 780771-39-3P, Acetic acid 2-(1-methyl-2-(phenethyl)carbamoyl)propenyl)carbamoylphenyl ester 780771-49-5P, 3-Amino-2-isopropylbut-3-enoic acid methyl ester 780771-50-8P, 2-Isopropyl-3-(2-methoxybenzoylamino)but-3-enoic acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinone compds. as calcilytics)

STRUCTURE SEARCH

```
=> fil casre; d stat que l20;s l20 not l29; fil reg; d stat que l36; fil capl; d
que nos l37; s l37 not l41
FILE 'CASREACT' ENTERED AT 14:37:44 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 26 Jan 2008 VOL 148 ISS 5


New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*   CASREACT now has more than 13.8 million reactions   *
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR



NODE ATTRIBUTES:


```
NSPEC  IS RC      AT   8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:

```
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8
```

STEREO ATTRIBUTES: NONE

```
L2      448706 SEA FILE=REGISTRY SSS FUL L1
L4      46492 SEA FILE=REGISTRY ABB=ON  L2 AND CASREACT/LC
L5      10919 SEA FILE=CASREACT ABB=ON  L4
L8      STR
```



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED





GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

MAPPINGS

NOD	SYM	ROL	NOD	SYM	ROL
2	C	RRT	6	C	PRO
3	N	RRT	7	N	PRO
4	O	RRT	11	O	PRO
6	C	PRO	2	C	RRT
7	N	PRO	3	N	RRT
11	O	PRO	4	O	RRT

L11 1257 SEA FILE=CASREACT SUB=L5 SSS FUL L8 (11881 REACTIONS)
 L12 1118 SEA FILE=CASREACT ABB=ON L11/COMPLETE
 L13 902 SEA FILE=CASREACT ABB=ON L12 AND (PY<2004 OR AY<2004 OR
 PRY<2004)
 L16 STR



VAR G1=14/32/37
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 20
 CONNECT IS E2 RC AT 29
 CONNECT IS E2 RC AT 44
 DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L19 22 SEA FILE=CASREACT SUB=L11 SSS FUL L16 (56 REACTIONS)
L20 16 SEA FILE=CASREACT ABB=ON L13 AND L19

L43 14 L20 NOT L29

FILE 'REGISTRY' ENTERED AT 14:37:45 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6
DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L1 STR





NODE ATTRIBUTES:

NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
 L2 448706 SEA FILE=REGISTRY SSS FUL L1
 L33 STR



Page 1-A



Page 2-A

VAR G1=OH/OME
 VAR G2=23/24
 VAR G3=23/CF3
 REP G4=(1-2) C
 VAR G5=1/61/30
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 23
 CONNECT IS E2 RC AT 65
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY LOC UNS AT 66
 GGCAT IS MCY LOC UNS AT 67
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 69

STEREO ATTRIBUTES: NONE

L36 82 SEA FILE=REGISTRY SUB=L2 SSS FUL L33

100.0% PROCESSED 21805 ITERATIONS
SEARCH TIME: 00.00.01

82 ANSWERS

FILE 'CAPLUS' ENTERED AT 14:37:45 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1 STR
L2 448706 SEA FILE=REGISTRY SSS FUL L1
L33 STR
L36 82 SEA FILE=REGISTRY SUB=L2 SSS FUL L33
L37 5 SEA FILE=CAPLUS ABB=ON L36/P

L44 4 L37 NOT L41

=> dup rem l43,l44

FILE 'CASREACT' ENTERED AT 14:38:00 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 14:38:00 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L43
PROCESSING COMPLETED FOR L44


L45 18 DUP REM L43 L44 (0 DUPLICATES REMOVED)
ANSWERS '1-14' FROM FILE CASREACT
ANSWERS '15-18' FROM FILE CAPLUS

=> d ibib abs fhit 1-14; d ibib abs hitstr 15-18; fil hom

L45 ANSWER 1 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 134:86206 CASREACT [Full-text](#)
 TITLE: The behaviour of some nucleophiles towards
 2-[α -(benzoylamino)- β -(2-
 thienyl)vinyl]benzoxazin-4(3H)-one
 AUTHOR(S): Guirguis, Dalal B.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Ain Shams
 University, Cairo, Egypt
 SOURCE: Indian Journal of Chemistry, Section B: Organic
 Chemistry Including Medicinal Chemistry (2000
), 39B(4), 264-269
 CODEN: IJSBDB; ISSN: 0376-4699
 PUBLISHER: National Institute of Science Communication, CSIR
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB 2-[α -(Benzoylamino)- β -thien-2-ylvinyl]benzoxazin-4(3H)-one (I) undergoes ring-
 opening on treatment with primary and secondary amines affording 2-[α -
 (benzoylamino)- β -thien-2-ylacrylamido]benzamides. Treatment of I with HCONH₂
 and N₂H₄.H₂O at elevated temperature gives rise to quinazolinones.
 Interestingly, reaction of vicinal aminobenzyl alcs. with I yields the usual
 ring-opening products and unexpected 4-iminobenzoxazines.

RX(9) OF 80 ...F ==> T



RX(9) RCT F 318292-64-7

STAGE(1)
 RGT U 75-12-7 Formamide
 SOL 64-17-5 EtOH


STAGE(2)
 SOL 7732-18-5 Water

PRO T 318292-72-7

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L45 ANSWER 2 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 138:106647 CASREACT [Full-text](#)

TITLE: Quinazolinones derived from N-(1,1-dimethylacetonyl)benzamide
 AUTHOR(S): Usifoh, C. O.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, University of Benin, Benin City, Nigeria
 SOURCE: Nigerian Journal of Chemical Research (2000), 5, 39-42
 CODEN: NJCRBW; ISSN: 1119-0221
 PUBLISHER: Nigerian Journal of Chemical Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Ring opening of isatoic anhydride with 1,1-dimethyl-2-propynylamine at 45° in DMF gave 2-H₂NC₆H₄CONHCMe₂R (I, R = C.tplbond.CH), while refluxing isatoic anhydride with 1,1-dimethyl-2-propynylamine at 100° in water afforded I (R = COMe). When I (R = C.tplbond.CH) was refluxed in formic acid-water, I (R = COMe) was also obtained, and on cyclization with triphosgene and tri-Et orthoacetate it yielded the quinazolinones II and III, resp.

RX(4) OF 12 ...I + E ==> J




YIELD 70%

RX(4) RCT I 32315-10-9, E 485322-54-1
 RGT K 121-44-8 Et3N
 PRO J 485322-55-2
 SOL 123-91-1 Dioxane
 CON SUBSTAGE(1) 0 deg C
 SUBSTAGE(2) 6 hours, reflux


REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L45 ANSWER 3 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 129:109322 CASREACT [Full-text](#)
 TITLE: Synthesis of 3-dipeptidyl-2,4(1H,3H)-quinazoliniones
 as potential anti-hypertensive agents
 AUTHOR(S): Rivero, I. A.; Somanathan, R.; Hellberg, L. H.
 CORPORATE SOURCE: Centro de Graduados e Investigacion del Instituto
 Tecnologico de Tijuana, Tijuana, 22000, Mex.
 SOURCE: Synthetic Communications (1998), 28(11),
 2077-2086
 CODEN: SYNCAV; ISSN: 0039-7911
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Quinazoliniones I (R = Trp-OMe, Phe-OEt, Pro-OMe, Gly-OEt, DL-Ala-OMe)
 bearing a dipeptide moiety have been synthesized as potential anti-
 hypertensive agents (no data given).

RX(1) OF 9 A + B ==> C...





C


RX(1) RCT A 5973-34-2, B 75-09-2
 PRO C 58004-83-4
 NTE 2 H, 20.deg.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L45 ANSWER 4 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 128:13283 CASREACT Full-text
 TITLE: Preparation of dioxoquinazolines
 INVENTOR(S): Ueda, Hiroshi; Komatsu, Satoshi; Nishii, Shinji
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09291080	A	19971111	JP 1996-105647	19960425

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 128:13283
 GI




I





II

AB Title compds. I [R1, R2 = H, halo, NO2, lower (halo)alkyl, (halo)aralkyl, (halo)alkoxy, (halo)alkoxycarbonyl, YNR3R4; R3, R4 = lower alkyl; R3R4 may form ring; Y = bond, lower alkylene, CO; X = lower (halo)alkyl, (halo)aralkyl, ZCO2R5; R5 = lower alkyl, aralkyl; Z = lower alkylene], useful as intermediates for antiinflammatories, drugs for diabetic complications, etc., are prepared by treating anthranilamides II (R1, R2, X = same as I) with COCl2. II (R1 = R2 = H, X = CH2CO2Et) was treated with COCl2 and NEt3 in THF at 5° for 90 min to give 98% I (R1 = R2 = H, X = CH2CO2Et).



AB Title compds. I (R = alkyl; R1 = alkyl, alkoxy, halo, etc.; X = alkylene; n = 0-4) were prepared from amino carboxylic acids II and orthocarbonate esters. Thus, 1.94 g II (X = CH2, n = 0) was refluxed with 4.1 g tetra-Me orthocarbonate for 4 h to give 1.4 g I (R = Me, X = CH2, n = 0).


RX(1) OF 1 A + B ==> C




RX(1) RCT A 1850-14-2, B 526-21-6
 PRO C 82603-69-8

L45 ANSWER 6 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 109:73469 CASREACT [Full-text](#)
 TITLE: Preparation of (1,2,3,4-tetrahydro-4-oxo-2-thioxoquinazolin-3-yl)-alkanoates as agrochemicals
 INVENTOR(S): Suesse, Manfred; Schaks, Angela; Johne, Siegfried
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SOURCE: Ger. (East), 5 pp.
 CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 252603	A1	19871223	DD 1986-294469	19860917
PRIORITY APPLN. INFO.:			DD 1986-294469	19860917
GI				




I




II

AB The title compds. [I; R = alkyl, alkoxy, halo, NO₂, CN, CF₃, alkoxycarbonyl, amino, acyl; R₂ = H, alkyl; X = (substituted) C1-10 alkylene; n = 0-4] useful as agrochems., for example as fungicides (no data), were prepared by cyclocondensation of (aminobenzoyl)amino acids II with CSCl₂ in H₂O or an organic solvent in the presence of a base, optionally followed by hydrolysis. o-Aminohippuric acid Me ester and Et₃N in CHCl₃ at 5° were treated with CSCl₂ in CHCl₃. The mixture was then stirred 2 h at room temperature and 30 min at 35° to give 44% I (n = 0, R₂ = Me, X = CH₂).

RX(1) OF 3 A ==> B...



A



B

RX(1) RCT A 82185-40-8
PRO B 85715-94-5

L45 ANSWER 7 OF 18 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 108:131849 CASREACT [Full-text](#)

TITLE: Preparation of 2-alkoxycarbonyl-3,4-dihydro-4-oxoquinazolin-3-yl-alkanoates as agrochemical fungicides

INVENTOR(S): Suesse, Manfred; Ermisch, Christine; John, Siegfried

PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.

SOURCE: Ger. (East), 4 pp.

CODEN: GEXXA8

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 247450	A1	19870708	DD 1986-288515	19860331

PRIORITY APPLN. INFO.:
GI



AB The title compds. (I; R1 = alkyl; R2 = alkyl, alkoxy, halo, CN, NO2, CF3; n = 0-4) were prepared as agrochem. fungicides (no data). A mixture of 3-(o-aminobenzoylamino)propanoic acid and excess di-Et oxalate was heated at 140° for 4 h to give 25% I (R1 = Et, X = CH2, 1 = 0).

RX(1) OF 1 A + B ==> C




RX(1) RCT A 13135-92-7, B 95-92-1
 PRO C 107466-56-8

L45 ANSWER 8 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 108:94592 CASREACT [Full-text](#)
TITLE: Preparation of 2-(alkoxycarbonyl)-4-oxo-3-quinazolinealkanoates as agrochemical fungicides

INVENTOR(S): Suesse, Manfred; Ermisch, Christine; Johne, Siegfried
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SOURCE: Ger. (East), 4 pp.
 CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 247449	A1	19870708	DD 1986-288514	19860331

PRIORITY APPLN. INFO.: DD 1986-288514 19860331
 GI




AB The title compds. (I; R1 = alkyl; R2 = alkyl, alkoxy, halo, CN, NO2, CF3; X = Cl-10 alkylene; n = 0-4) were prepared as agrochem. fungicides (no data). To a 10° solution of Et 2-amino-hippurate in MeCN were added Et3N and ClCOCO2Et. The temperature was gradually raised to 80° over 1 h and the mixture was stirred for another 30 min to give 10% I (R1 = Et, X = CH2, n = 0).

RX(1) OF 1 A + B ==> C





RX(1) RCT A 5973-34-2, B 4755-77-5
PRO C 64697-12-7

L45 ANSWER 9 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 106:138387 CASREACT [Full-text](#)
TITLE: Quinazolinecarboxylic acid. Synthesis of
alkyl[2-(ethoxycarbonyl)-3,4-dihydro-4-oxoquinazolin-3-
yl]-, [2-(ethoxycarbonyl)quinazolin-4-yloxy]- and
(5,6,7,8-tetrahydro-2-phenylquinazolin-4-
ylthio)alkanoates
AUTHOR(S): Suesse, Manfred; Adler, Frank; John, Siegfried
CORPORATE SOURCE: Inst. Biochem. Pflanzen Halle, Dtsch. Akad. Wiss.,
Halle/Saale, DDR-4010, Ger. Dem. Rep.
SOURCE: Helvetica Chimica Acta (1986), 69(5),
1017-24
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB Cyclization of 2-H₂NC₆H₄CONH(CH₂)_nCO₂Et (I, n = 2, 3) with EtO₂CCO₂Et gave quinazolines II (R = Et, R₁ = CO₂Et), whereas, condensation of I (n = 1) with ClCOCO₂Et gave a mixture of 2-EtO₂CCONHC₆H₄CONHCH₂CO₂Et and II (n = 1, R = Et, R₁ = CO₂Et). Cyclization of 2-H₂NC₆H₄CONH₂ (III) with EtO₂CCO₂Et followed by condensation with BrCH₂CO₂R (R = Me, Et) gave II (n = 1, R = Me, Et, R₁ = CO₂Et), whereas, cyclization of III with EtO₂CCO₂Et followed by condensation with R₂CH₂CHBrCO₂Et (R₂ = H, Me) gave quinazoline esters IV. Condensation of III with ClCOCH₂CH₂CO₂Me gave 2-H₂NCOC₆H₄NHCOCH₂CH₂CO₂Me which was cyclized with BrCH₂CO₂Et to give II (n = 1, R = Et, R₁ = CH₂CH₂CO₂CH₂CO₂Et). Quinazoline thioethers V (R₃ = Me, Et, R₄ = H, Et, CHMe₂) were prepared by aminolysis of 5,6,7,8-tetrahydro-1,3-benzoxazine-4(3H)-thione followed by condensation with BrCHR₄CO₂R₃.

RX(1) OF 27 A + B ==> C



C
YIELD 25%

RX(1) RCT A 13135-92-7, B 95-92-1
PRO C 107466-56-8

L45 ANSWER 10 OF 18 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 106:102208 CASREACT [Full-text](#)

TITLE: Quinazolinecarboxylic acids. 5. Synthesis of 1,4-dihydroquinazolin-4-on-1-ylacetic acids and esters

AUTHOR(S): Suesse, Manfred; Johne, Siegfried

CORPORATE SOURCE: Inst. Biochem. Pflanzen, Dtsch. Akad. Wiss., Halle, DDR-4020, Ger. Dem. Rep.


SOURCE: Monatshefte fuer Chemie (1986), 117(4), 499-509

CODEN: MOCMB7; ISSN: 0026-9247

DOCUMENT TYPE: Journal



LANGUAGE: German

GI



AB Cyclization of aminobenzamides I (R = H, Cl, Br; R1 = Me, Et), prepared by reaction of benzoxazinediones II with NH₃, with HC(OEt)₃ gave esters III (R2 = H), hydrolysis of III lead to the title acids III (R1 = H). 2-Substituted quinazolinones III (R2 = Me, Et, Ph, 4-O₂NC₆H₄, 4-HOC₆H₄, 2-ClC₆H₄) could be obtained by reaction of I with acid chlorides or by reaction of II with amidines. Quinazolinone IV was synthesized in a similar way. The amide 2-H₂NC₆H₄CONHCH₂CO₂Me showed reaction behavior different from that of I.

RX(27) OF 48 AT + AU ==> AV



AV
YIELD 36%

RX(27) RCT AT 92185-40-8, AU 707-07-3
PRO AV 106634-20-2

L45 ANSWER 11 OF 18 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 105:208821 CASREACT [Full-text](#)

TITLE: A facile one pot synthesis of 2,9-disubstituted 8-azapurin-6-ones (3,5-disubstituted 7-hydroxy-3H-1,2,3-triazolo[4,5-d]pyrimidines)

AUTHOR(S): Barili, Pier Luigi; Biagi, Giuliana; Livi, Oreste; Scartoni, Valerio

CORPORATE SOURCE: Ist. Chim. Org., Univ. Pisa, Pisa, 56100, Italy


SOURCE: Journal of Heterocyclic Chemistry (1985), 22(6), 1607-9

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal



LANGUAGE: English

GI



AB Cyclization of $\text{NCCH}_2\text{CONH}_2$, PhCH_2N_3 , and RCO_2R_1 [$\text{R} = \text{H, Me, Et, Pr, MeOCH}_2\text{CH}_2$, CH(OEt)_2 , $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$, CO_2Et , Ph , PhCH_2 , BzNHCH_2 ; $\text{R}_1 = \text{Me, Et}$] gave 43-95% title compds. I.

RX(2) OF 11 A + B + G ==> H



RX(2) RCT A 107-91-5, B 622-79-7

STAGE(1)

RGT E 141-52-6 NaOEt

SOL 64-17-5 EtOH

STAGE(2)

RCT G 141-78-6

SOL 64-17-5 EtOH

PRO H 71492-05-2

L45 ANSWER 12 OF 18 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

106:32964 CASREACT Full-text

TITLE:

Quinazolinocarboxylic acids. IX. Synthesis and reactions of 2-ureidohippuric acids and their esters


AUTHOR(S):

Suesse, Manfred; Johne, Siegfried

CORPORATE SOURCE:


Inst. Biochem. Pflanzen Halle, Dtsch. Akad. Wiss., Halle/Saale, DDR-4020/3, Ger. Dem. Rep.

SOURCE: Zeitschrift fuer Chemie (1985), 25(11),
403-4
CODEN: ZECEAL; ISSN: 0044-2402
DOCUMENT TYPE: Journal
LANGUAGE: German
GI




AB The aminohippuric acids I (R = H, 5-Br, 3,5-Br₂, 3,5-Cl₂; R₁ = H, Me; R₂ = H) were treated with K₂CN₂ to give the ureido derivs. I (R₂ = CONH₂). I (R = 5-Br, R₁ = Me, R₂ = CONH₂) was heated at 200-210° under N to give the quinazoline II (R₃ = CH₂CO₂Me). I (R = H, R₁ = Me, R₂ = CONH₂) was treated with KOH in EtOH to give II (R₃ = H).

RX(7) OF 12 ...H ==> O




H



O



RX(7) RCT H 105217-21-2
 PRO O 106047-54-5
 SOL 7727-37-9 N2

L45 ANSWER 13 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 96:85497 CASREACT Full-text
 TITLE: 2-[(Acylamino)methyl]-6-methylpyrimidin-4(3H)-ones.
 Novel precursors for the synthesis of
 imidazo[1,5-a]pyrimidines and imidazo[4,5-b]pyridines
 Katagiri, Nobuya; Koshihara, Akemi; Atsuumi, Shugo;
 Kato, Tetsuzo
 AUTHOR(S): Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
 CORPORATE SOURCE: Journal of Organic Chemistry (1982), 47(1),
 SOURCE: 167-9
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Pyrimidinones I (R = Me, CHMe₂, Ph), prepared from 3-aminocrotonamide and Et N-acylglycinates, are novel and versatile precursors for the preparation of imidazopyrimidines II (R = Me, CHMe₂) and imidazopyridines III (R = Me, CHMe₂, Ph).

RX(3) OF 30 F + G ==> H...




H
 YIELD 71%

RX(3) RCT F 15846-25-0, G 1906-82-7
 PRO H 79898-99-0

L45 ANSWER 14 OF 18 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 96:162734 CASREACT [Full-text](#)
 TITLE: Quinazoline-2,4-dione-3-acetic acids
 INVENTOR(S): Suesse, Manfred; Johne, Siegfried
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SOURCE: Ger. (East), 16 pp.
 CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 151308	A1	19811014	DD 1980-221623	19800606
PRIORITY APPLN. INFO.:			DD 1980-221623	19800606


GI



AB Quinazolidinediones I (R, R1 = H, halogen, NO2, alkyl, alkoxy, CO2H) were prepared Thus 6,8-dibromoisatoic anhydride was treated with H2NCH2CO2Me.HCl to give 90% 2,3,5-H2N(Br)2C6H2CONHCH2CO2Me which was cyclized with ClCO2Et and saponified to give 50% I (R = R1 = Br).

RX(6) OF 13 ...F + D ==> H





H

RX(6) RCT F 81438-16-6, D 541-41-3
PRO H 81438-17-7

L45 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:591360 CAPLUS Full-text

DOCUMENT NUMBER: 147:31135

TITLE: Pyrimidinone derivatives as calcilytic compounds and their preparation, pharmaceutical compositions and use as calcium receptor inhibitors for treatment of bone and mineral diseases

INVENTOR(S): Ku, Thomas Wen Fu; Lin, Hong; Luengo, Juan I.; Marquis, Robert W., Jr.; Ramanjulu, Joshi M.; Trout, Robert; Yamashita, Dennis S.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 251pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062370	A2	20070531	WO 2006-US61150	20061121
WO 2007062370	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2005-738731P P 20051122
US 2005-739067P P 20051122

OTHER SOURCE(S): MARPAT 147:31135

GI



AB Novel calcilytic compds. of formula I, pharmaceutical compns., methods of synthesis and methods of using them are provided. Compds. of formula I wherein C is O and S; R1 and R2 are independently H, halo, CN, C1-10 alkyl, C2-6 alkenyl, cycloalkyl, (hetero)aryl, etc.; R3 is (un)substituted (hetero)aryl; R4 is (un)substituted (hetero)aryl, (un)substituted heterocyclyl, (un)substituted cycloalkyl-C1-4 alkyl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by alkylation of Et 3-oxobutanoate with 3-bromo-2-methyl-1-propene; the resulting Et 2-acetyl-4-methyl-4-pentenoate underwent amidation with phenethylamine to give 2-acetyl-4-methyl-N-(phenethyl)-4-pentanamide, which underwent hydrogenation to give 2-acetyl-4-methyl-N-(phenethyl)-4-pentanamide, which underwent cyclization with 2-fluoro-3-methoxybenzamide to give 2-(2-fluoro-3-methoxyphenyl)-6-methoxy-5-(2-methylpropyl)-3-(2-phenylethyl)-4(3H)-pyrimidinone, which underwent demethylation to give compound II. All the invention compds. were evaluated for their calcium receptor inhibitory activity.


IT 938179-15-8P 938179-98-7P 938180-14-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidinone derivs. as calcium receptor inhibitors useful in the treatment of bone and mineral diseases)


RN 938179-15-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 938179-98-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-5-(2-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)



RN 938180-14-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)-5-propyl- (CA INDEX NAME)



IT 780771-55-3P 938177-03-8P 938177-43-6P

938177-48-1P 938177-52-7P 938177-71-0P

938177-76-5P 938177-80-1P 938177-82-3P

938178-59-7P 938178-60-0P 938178-63-3P

938178-65-5P 938178-66-6P 938178-79-1P

938178-80-4P 938178-81-5P 938178-90-6P

938178-91-7P 938178-98-4P 938178-99-5P

938179-00-1P 938179-01-2P 938179-02-3P

938179-08-9P 938179-16-9P 938179-21-6P

938179-22-8P 938179-33-0P 938179-42-1P

938179-44-3P 938179-45-4P 938179-47-6P

938179-49-8P 938179-50-1P 938179-51-2P


938179-54-5P 938179-99-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinone derivs. as calcium receptor inhibitors useful in the treatment of bone and mineral diseases)


RN 780771-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 938177-03-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2,3-dihydroxyphenyl)-6-methyl-5-(2-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938177-43-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3,6-difluoro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 938177-48-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-5,5-dimethyl- (CA INDEX NAME)




RN 938177-52-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluoro-2-hydroxyphenyl)-5,6,7,8-tetrahydro-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938177-71-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5,6-diethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 938177-76-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




RN 938177-80-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(4-fluorophenyl)ethyl]-6-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




RN 938177-82-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




RN 938178-59-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-5-(2-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-60-0 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-5-(2-methyl-2-propen-1-yl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-63-3 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-6,6-dimethyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-65-5 CAPLUS

CN 4(3H)-Pyrimidinone, 5-cyclopropyl-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-66-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-5-(3-methylbutyl)- (CA INDEX NAME)




RN 938178-79-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5-(2-methylpropyl)-3-(2-phenylethyl)-6-propyl- (CA INDEX NAME)




RN 938178-80-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-ethyl-2-(2-hydroxyphenyl)-5-(2-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-81-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-butyl-2-(2-hydroxyphenyl)-5-(2-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-90-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(2-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 938178-91-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-5,5-dimethyl- (CA INDEX NAME)




RN 938178-98-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-5-(1-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938178-99-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-5-(1-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938179-00-1 CAPLUS

CN 4(3H)-Pyrimidinone, 5-butyl-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)-
(CA INDEX NAME)




RN 938179-01-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-5-pentyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938179-02-3 CAPLUS

CN 4(3H)-Pyrimidinone, 5-hexyl-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938179-08-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 938179-16-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-5-(1-propen-1-yl)- (CA INDEX NAME)




RN 938179-21-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 938179-23-8 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-3-[2-(3-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)



RN 938179-33-0 CAPLUS


CN 4(3H)-Pyrimidinone, 5-(1,1-dimethylethyl)-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938179-42-1 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-


methyl-5-(2-methylpropyl)- (CA INDEX NAME)



RN 938179-44-3 CAPLUS


CN 4(3H)-Pyrimidinone, 5,6-diethyl-2-(2-hydroxyphenyl)-3-(2-phenylethyl)-
(CA INDEX NAME)

RN 938179-45-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-3-(2-phenylethyl)-6-propyl-
(CA INDEX NAME)


RN 938179-47-6 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-propyl- (CA INDEX NAME)




RN 938179-49-8 CAPLUS

CN 4(3H)-Pyrimidinone, 6-butyl-5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 938179-50-1 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-(2-methylpropyl)- (CA INDEX NAME)




RN 938179-51-2 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-(3-methylbutyl)- (CA INDEX NAME)




RN 938179-54-5 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(4-fluoro-2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



RN 938179-99-8 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-5,5-dimethyl-3-(2-phenylethyl)- (CA INDEX NAME)



IT 938180-43-9P 938180-58-6P 938181-03-4P

938181-16-9P 938181-18-1P 938181-44-3P


938181-72-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidinone derivs. as calcium receptor inhibitors useful in the treatment of bone and mineral diseases)


RN 938180-43-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3,6-difluoro-2-methoxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 938180-58-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-methoxyphenyl)-3-[2-(2-fluorophenyl)ethyl]-6-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




RN 938181-03-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(2-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 938181-16-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-methoxyphenyl)-6-methyl-5-(1-methylpropyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938181-18-1 CAPLUS

CN 4(3H)-Pyrimidinone, 5-butyl-2-(2-methoxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 938181-44-3 CAPLUS

CN 4(3H)-Pyrimidinone, 5,6-diethyl-2-(2-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)



RN 938181-72-7 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-methoxyphenyl)-5,5-dimethyl-3-(2-phenylethyl)- (CA INDEX NAME)



L45 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:605352 CAPLUS Full-text

DOCUMENT NUMBER: 145:83371

TITLE: Preparation of prodrug constructs of pyrimidinone compounds as calcilytics

INVENTOR(S): Shcherbakova, Irina; Wermuth, Camille G.; Jeannot, Frederic; Ciapetti, Paola; Roques, Virginie; Jung, Laetitia M.; Balandrin, Manuel F.; Nair, Satheesh, K.; Swierczek, Krzysztof; McCaffrey, Jennifer; Heaton, William L.; Breinholt, Jeff A.; Conklin, Rebecca L. NPS Pharmaceuticals, Inc., USA

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066070	A2	20060622	WO 2005-US45565	20051216
WO 2006066070	A3	20060921		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-637115P P 20041217

OTHER SOURCE(S): MARPAT 145:83371

GI



AB Calcilytic pyrimidinones I [R1 and R2 = H, halo, CN, CF₃, etc.; R3 = (un)substituted aryl group; R4 = H, alkyl, aryl, etc.], and prodrugs as well as pharmaceutically acceptable salts thereof, are prepared for use in treating disease or disorders characterized by abnormal bone or mineral homeostasis. Thus, e.g., II was prepared by amidation of anisoyl chloride with 2-amino-2-isopropylbut-2-enoic acid Me ester (preparation given) followed by cyclization with 3-fluorophenethyl amine and demethylation. Calcilytic compds. are compds. capable of inhibiting calcium receptor activity. Assays for determining calcium receptor inhibition are described with parameter of desirable IC₅₀ values given. Methods for preparing these compds., oral bioavailability of these compds., pharmaceutical compns. containing these compds. and their use as calcium receptor antagonists are also disclosed.


IT 780771-48-4P 893053-18-4P 893053-34-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of prodrug constructs of pyrimidinone compound as calcilytics)


RN 780771-48-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 893053-18-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-methoxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)



RN 893053-34-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




IT 893053-26-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prodrug constructs of pyrimidinone compound as calcilytics)

RN 893053-26-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




IT 893054-83-6P 893054-99-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prodrug constructs of pyrimidinone compound as calcilytics)

RN 893054-83-6 CAPLUS


CN 4(3H)-Pyrimidinone, 5-(1,2-dimethylpropyl)-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



RN 893054-99-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-5-methyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 786771-51-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of prodrug constructs of pyrimidinone compound as calcilytics)

RN 780771-51-9 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-methoxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)



L45 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:378882 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:59927

TITLE: Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones

AUTHOR(S): Shcherbakova, Irina; Huang, Guangfei; Geoffroy, Otto J.; Nair, Satheesh K.; Swierczek, Krzysztof; Balandrin, Manuel F.; Fox, John; Heaton, William L.; Conklin, Rebecca L.

CORPORATE SOURCE: Drug Discovery, NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2537-2540

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:59927


GI




- AB Design, synthesis, structure-activity relationship studies and calcium receptor antagonist (calcilytic) properties of 3H-pyrimidin-4-ones, e.g., I, are described. The pyrimidinones were synthesized by multistep procedures.
- IT 780771-35-9P 780771-41-7P 780771-43-9P
 780771-44-0P 780771-47-3P 780771-48-4P
 780771-53-1P 780771-54-2P 780771-55-3P
 780771-56-4P 780771-57-5P 780771-58-6P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, calcilytic activity, and structure-activity relationship of substituted pyrimidinones starting from hydroxybenzonitrile or β -keto esters and phenylethylamines using multistep procedures)
- RN 780771-35-9 CAPLUS
- CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5,6-dimethyl-3-(2-phenylethyl)- (CA INDEX NAME)



- RN 780771-41-7 CAPLUS
- CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




- RN 780771-43-9 CAPLUS
- CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-44-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-47-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-propyl- (CA INDEX NAME)




RN 780771-48-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-53-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5-methyl-3-(2-phenylethyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 780771-54-2 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 780771-56-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-57-5 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 780771-58-6 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3-[2-(3-fluorophenyl)ethyl]-3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L45 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:902338 CAPLUS Full-text

DOCUMENT NUMBER: 141:366249

TITLE: Preparation of pyrimidinone compounds as calcilytics
Shcherbakova, Irina V.; Balandrin, Manuel F.; Huang,INVENTOR(S): Guangfei; Geoffroy, Otto; Fox, John; Marquis, Robert;
Yamashita, Dennis Shinji; Luengo, Juan; Wang, Wenyong

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA; Glaxosmithkline

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092120	A2	20041028	WO 2004-US10638	20040407
WO 2004092120	A3	20050414		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004230903	A1	20041028	AU 2004-230903	20040407

CA 2521129 A1 20041028 CA 2004-2521129 20040407
 EP 1615897 A2 20060118 EP 2004-749814 20040407
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 CN 1835928 A 20060920 CN 2004-80009255 20040407
 JP 2006522159 T 20060928 JP 2006-509758 20040407
 MX 2005PA10683 A 20060801 MX 2005-PA10683 20051004
 US 2007197555 A1 20070823 US 2006-552363 20061120
 PRIORITY APPLN. INFO.: US 2003-460859P P 20030407
 US 2003-479323P P 20030618
 WO 2004-US10638 W 20040407
 OTHER SOURCE(S): CASREACT 141:366249; MARPAT 141:366249
 GI




AB Title compds. I [R1-2 = H, halo, CN, CF3, etc.; R3 = aryl; R4 = H, alkyl, etc.] are prepared For instance, 2-(2-Hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one is prepared from o-hydroxybenzonitrile, acetyl chloride and Me acetoacetate. Compds. of the invention have IC50 values < 30 μM in a calcium receptor inhibition assay. I are useful for the treatment of abnormal bone or mineral homeostasis.

IT 780771-43-9P, 5-Ethyl-2-(2-hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one 780771-51-9P, 3-[2-(3-Fluorophenyl)ethyl]-5-isopropyl-2-(2-methoxyphenyl)-6-methyl-3H-pyrimidin-4-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrimidinone compds. as calcilytics)


RN 780771-43-9 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



RN 780771-51-9 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-methoxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)



IT 780771-35-9F, 2-(2-Hydroxyphenyl)-5,6-dimethyl-3-phenethyl-3H-pyrimidin-4-one 780771-40-6F, 3-[2-(2-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-41-7F, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-42-6F, 3-[2-(4-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl-3H-pyrimidin-4-one 780771-44-0P, 5-Ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-45-1P 780771-46-2P, 5-Ethyl-3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-47-3F, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-propyl-3H-pyrimidin-4-one 780771-48-4P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-isopropyl-6-methyl-3H-pyrimidin-4-one 780771-52-0F, 3-[2-(2-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-isopropyl-6-methyl-3H-pyrimidin-4-one 780771-53-1P, 2-(2-Hydroxyphenyl)-5-methyl-3-phenethyl-6-trifluoromethyl-3H-pyrimidin-4-one 780771-54-2P, 2-(2-Hydroxyphenyl)-3-phenethyl-5,6,7,8-tetrahydro-3H-quinazolin-4-one 780771-55-3P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one 780771-56-4P, 5-Cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-3H-pyrimidin-4-one 780771-57-5P, 2-(2-Hydroxyphenyl)-3-phenethyl-3,5,6,7-tetrahydrocyclopenta[1,2-d]pyrimidin-4-one 780771-58-6P, 3-[2-(3-Fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-3,5,6,7-tetrahydrocyclopenta[1,2-d]pyrimidin-4-one 780771-59-7P, 5-Ethyl-2-(2-methoxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one 780771-62-2P, 5-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-64-4P, 5-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-65-5P, 5-Ethyl-2-(2-fluoro-6-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-67-7P, 2-(5-Chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-68-8P, 2-(5-Bromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-69-9P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-3-isopropylphenyl)-6-methyl-3H-pyrimidin-4-one 780771-71-3P, 2-(3,5-Dibromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-72-4P, 5-Ethyl-2-(3-chloro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-74-6P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-3-methylphenyl)-6-methyl-3H-pyrimidin-4-one 780771-75-7P, 2-(4-Chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl-3H-pyrimidin-4-one 780771-76-8P, 5-Ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-4-methoxyphenyl)-6-methyl-3H-pyrimidin-4-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinone compds. as calcilytics)

RN 780771-35-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5,6-dimethyl-3-(2-phenylethyl)-

(CA INDEX NAME)




RN 780771-40-6 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-41-7 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-42-8 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 780771-44-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-45-1 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-46-2 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-47-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-propyl- (CA INDEX NAME)




RN 780771-48-4 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-52-0 CAPLUS

CN 4(3H)-Pyrimidinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 780771-53-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5-methyl-3-(2-phenylethyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 780771-54-2 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 780771-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 780771-56-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-57-5 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 780771-58-6 CAPLUS

CN 4H-Cyclopentapyrimidin-4-one, 3-[2-(3-fluorophenyl)ethyl]-3,5,6,7-tetrahydro-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 780771-59-7 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-methoxyphenyl)-6-methyl-3-(2-phenylethyl)-
(CA INDEX NAME)


RN 780771-62-2 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-64-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(5-fluoro-2-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-65-5 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-fluoro-6-hydroxyphenyl)-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-67-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(5-chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-68-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(5-bromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-69-9 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(3-fluorophenyl)ethyl]-2-[2-hydroxy-3-(1-methylethyl)phenyl]-6-methyl- (CA INDEX NAME)




RN 780771-71-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3,5-dibromo-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-72-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)




RN 780771-74-6 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-3-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 780771-75-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-hydroxyphenyl)-5-ethyl-3-[2-(3-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)



RN 780771-76-8 CAPLUS


CN 4(3H)-Pyrimidinone, 5-ethyl-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxy-4-methoxyphenyl)-6-methyl- (CA INDEX NAME)



FILE 'HOME' ENTERED AT 14:38:47 ON 01 FEB 2008

SEARCH HISTORY

=> d stat que l36; d stat que l20; d his nofile
 L1 STR



NODE ATTRIBUTES:



NSPEC IS RC AT 8
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L2 448706 SEA FILE=REGISTRY SSS FUL L1
 L33 STR



Page 1-A



Page 2-A
 VAR G1=OH/OME
 VAR G2=23/24
 VAR G3=23/CF3
 REP G4=(1-2) C
 VAR G5=1/61/30
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 23
 CONNECT IS E2 RC AT 65
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY LOC UNS AT 66
 GGCAT IS MCY LOC UNS AT 67
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 69

STEREO ATTRIBUTES: NONE
 L36 82 SEA FILE=REGISTRY SUB=L2 SSS FUL L33

100.0% PROCESSED 21805 ITERATIONS
 SEARCH TIME: 00.00.01

82 ANSWERS


L1 STR



NODE ATTRIBUTES:
 NSPEC IS RC AT 8
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
 L2 448706 SEA FILE=REGISTRY SSS FUL L1
 L4 46492 SEA FILE=REGISTRY ABB=ON L2 AND CASREACT/LC
 L5 10919 SEA FILE=CASREACT ABB=ON L4
 L8 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED





GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

MAPPINGS

NOD	SYM	ROL	NOD	SYM	ROL
2	C	RRT	6	C	PRO
3	N	RRT	7	N	PRO
4	O	RRT	11	O	PRO
6	C	PRO	2	C	RRT
7	N	PRO	3	N	RRT
11	O	PRO	4	O	RRT

L11 1257 SEA FILE=CASREACT SUB=L5 SSS FUL L8 (11881 REACTIONS)
 L12 1118 SEA FILE=CASREACT ABB=ON L11/COMPLETE
 L13 902 SEA FILE=CASREACT ABB=ON L12 AND (PY<2004 OR AY<2004 OR
 PRY<2004)
 L16 STR



VAR G1=14/32/37
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 20
 CONNECT IS E2 RC AT 29
 CONNECT IS E2 RC AT 44
 DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L19 22 SEA FILE=CASREACT SUB=L11 SSS FUL L16 (56 REACTIONS)
L20 16 SEA FILE=CASREACT ABB=ON L13 AND L19

(FILE 'CAPLUS' ENTERED AT 11:20:31 ON 01 FEB 2008)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 12:04:27 ON 01 FEB 2008
ACT JAI920BAT/A

L1 STR
L2 448706 SEA SSS FUL L1

ACT JAI920REG/A

L3 39 SEA ABB=ON (116046-53-8/BI OR 128095-14-7/BI OR 1583-88-6/BI
OR 1655-07-8/BI OR 21615-34-9/BI OR 22396-14-1/BI OR 404-70-6/BI
I OR 51756-10-6/BI OR 52721-69-4/BI OR 5538-51-2/BI OR
607-97-6/BI OR 609-14-3/BI OR 611-10-9/BI OR 64-04-0/BI OR
780771-35-9/BI OR 780771-36-0/BI OR 780771-37-1/BI OR 780771-38
-2/BI OR 780771-39-3/BI OR 780771-40-6/BI OR 780771-41-7/BI OR
780771-42-8/BI OR 780771-43-9/BI OR 780771-44-0/BI OR 780771-45
-1/BI OR 780771-46-2/BI OR 780771-47-3/BI OR 780771-48-4/BI OR
780771-49-5/BI OR 780771-50-8/BI OR 780771-51-9/BI OR 780771-52
-0/BI OR 780771-54-2/BI OR 780771-55-3/BI OR 780771-56-4/BI OR
780771-57-5/BI OR 780771-58-6/BI OR 85796-29-8/BI OR 916335-88-
1/BI)

D SCAN

L4 46492 SEA ABB=ON L2 AND CASREACT/LC

FILE 'CASREACT' ENTERED AT 12:08:50 ON 01 FEB 2008
L5 10919 SEA ABB=ON L4

L6 STR
L7 21 SEA SUB=L5 SSS SAM L6 (86 REACTIONS)

FILE 'STNGUIDE' ENTERED AT 12:13:44 ON 01 FEB 2008

FILE 'CASREACT' ENTERED AT 12:18:01 ON 01 FEB 2008

FILE 'STNGUIDE' ENTERED AT 12:25:43 ON 01 FEB 2008

FILE 'CASREACT' ENTERED AT 12:29:29 ON 01 FEB 2008

L8 STR L6
L9 50 SEA SUB=L5 SSS SAM L8 (408 REACTIONS)
L10 4853 SEA SUB=L5 SSS FUL L8 (71375 REACTIONS) EXTEND
L11 1257 SEA SUB=L5 SSS FUL L8 (11881 REACTIONS)
L12 1118 SEA ABB=ON L11/COMPLETE
SAVE TEMP L12 JAI920CSRFL/A
L13 902 SEA ABB=ON L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'STNGUIDE' ENTERED AT 12:32:35 ON 01 FEB 2008

FILE 'CASREACT' ENTERED AT 12:58:34 ON 01 FEB 2008

```

L14      STR L6
L15      0 SEA SUB=L11 SSS SAM L14 (      0 REACTIONS)
L16      STR L14
L17      1 SEA SUB=L11 SSS SAM L16 (      1 REACTIONS)
          D SCAN
L18      870 SEA SUB=L11 SSS FUL L16 (  7481 REACTIONS) EXTEND
L19      22 SEA SUB=L11 SSS FUL L16 (    56 REACTIONS)
          SAVE TEMP L19 JAI920SUB1/A
L20      16 SEA ABB=ON  L13 AND L19
          ACT JAI920CSRAU/A
          -----
L21 (    29)SEA ABB=ON  SHCHERBAKOVA I?/AU
L22 (     0)SEA ABB=ON  BALANDRIA M?/AU
L23 (   108)SEA ABB=ON  HUANG G?/AU
L24 (     5)SEA ABB=ON  GEOFFROY O?/AU
L25 (   117)SEA ABB=ON  FOX J?/AU
L26 (    51)SEA ABB=ON  NAIR S?/AU
L27 (     7)SEA ABB=ON  BALANDRIN M?/AU
L28      4 SEA ABB=ON  (L21 AND (L22 OR L23 OR L24 OR L25 OR L26 OR L27))
          OR (L23 AND (L24 OR L25 OR L26 OR L27)) OR (L24 AND (L25 OR
          L26 OR L27)) OR (L25 AND (L26 OR L27)) OR (L26 AND L27)
          -----
L29      4 SEA ABB=ON  L28 OR (L28 AND L11)

```

FILE 'REGISTRY' ENTERED AT 14:09:44 ON 01 FEB 2008

```

L30      STR
L31      12 SEA SUB=L2 SSS SAM L30

```

FILE 'ZCAPLUS' ENTERED AT 14:14:18 ON 01 FEB 2008

```

L32      2 SEA ABB=ON  L31
          D SCA TI

```

FILE 'REGISTRY' ENTERED AT 14:16:04 ON 01 FEB 2008

```

L33      STR
L34      2 SEA SUB=L2 SSS SAM L33
          D SCAN
L35      21805 SEA SUB=L2 SSS FUL L33 EXTEND
L36      82 SEA SUB=L2 SSS FUL L33
          SAVE TEMP L36 JAI920SUB2/A

```

FILE 'CAPLUS' ENTERED AT 14:29:07 ON 01 FEB 2008

```

L37      5 SEA ABB=ON  L36/P
          D SCAN TI
          ACT JAI920CAAU/A
          -----
L38      1 SEA ABB=ON  US2006-551920/AP
          -----
L39      1 SEA ABB=ON  L38 AND L37
          D SCAN

```

FILE 'CASREACT' ENTERED AT 14:31:11 ON 01 FEB 2008

FILE 'CAPLUS' ENTERED AT 14:33:03 ON 01 FEB 2008

```

L40      12524 SEA ABB=ON  L3
L41      1 SEA ABB=ON  L40 AND L38
          D QUE NOS L41

```

FILE 'CASREACT' ENTERED AT 14:34:13 ON 01 FEB 2008
D QUE NOS L29

L42 FILE 'CAPLUS, CASREACT' ENTERED AT 14:34:22 ON 01 FEB 2008
4 DUP REM L41 L29 (1 DUPLICATE REMOVED)
ANSWER '1' FROM FILE CAPLUS
ANSWERS '2-4' FROM FILE CASREACT
D IBIB ABS HITSTR 1
D IBIB ABS IND 3-4

FILE 'CASREACT' ENTERED AT 14:36:57 ON 01 FEB 2008

FILE 'CASREACT, CAPLUS' ENTERED AT 14:37:06 ON 01 FEB 2008
D IBIB ABS IND 3-4

FILE 'CASREACT' ENTERED AT 14:37:07 ON 01 FEB 2008

L43 FILE 'CASREACT' ENTERED AT 14:37:44 ON 01 FEB 2008
D STAT QUE L20
14 SEA ABB=ON L20 NOT L29

FILE 'REGISTRY' ENTERED AT 14:37:45 ON 01 FEB 2008
D STAT QUE L36

L44 FILE 'CAPLUS' ENTERED AT 14:37:45 ON 01 FEB 2008
D QUE NOS L37
4 SEA ABB=ON L37 NOT L41

L45 FILE 'CASREACT, CAPLUS' ENTERED AT 14:38:00 ON 01 FEB 2008
18 DUP REM L43 L44 (0 DUPLICATES REMOVED)
ANSWERS '1-14' FROM FILE CASREACT
ANSWERS '15-18' FROM FILE CAPLUS
D IBIB ABS FHIT 1-14
D IBIB ABS HITSTR 15-18

FILE 'HOME' ENTERED AT 14:38:47 ON 01 FEB 2008
D STAT QUE L36
D STAT QUE L20

=>